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Abstract  
  
Context 
Glycemic targets in diabetes have been developed to minimize complication risk.  Patients with 
heterozygous inactivating glucokinase (GCK) mutations have mild fasting hyperglycemia from 
birth, resulting in an elevated HbA1c that mimics recommended levels for type 1 and type 2 
diabetes. 
 
Objective 
To assess the association between chronic mild hyperglycemia and complication prevalence 
and severity in patients with GCK mutations 
 
Design, Setting and participants  
Cross sectional study in the UK between August 2008 and December 2010. Assessment of 
microvascular and macrovascular complications in participants ≥ 35 years was conducted in 99 
GCK mutation carriers (median age 48.6 years), 89 non-diabetic, familial non-mutation carriers 
(controls) (52.2 years), and 83 individuals with type 2 diabetes diagnosed at <45 years 
(YT2D)(54.7 years).   
 
Main outcome measures 
Prevalence and severity of retinopathy, nephropathy, peripheral neuropathy, peripheral 
vascular disease, and cardiovascular disease 
 
Results 
Median HbA1c was 6.9% in GCK patients 5.8% in controls, and 7.8% in YT2D patients. GCK 
patients had a low prevalence of clinically significant microvascular complications (1% [95% 
CI 0-6%]) that was not significantly different from controls (2% [0.2-8%], p=0.52) and lower 
than in YT2D patients (36% [25-47%], p<0.001).  Thirty percent of GCK patients had 
retinopathy (21-41%) compared to 14% of controls (7-23%, p=0.007) and 63% of YT2D 
patients (51-73%, p<0.001). Zero GCK patients or controls required laser therapy for 
retinopathy compared to 28% (18-39%) of the YT2D patients (p<0.001). Zero GCK patients or 
controls had proteinuria, and microalbuminuria was rare (GCK 1% [0.2-6%], controls 2% [0.2-
8%]), whereas 10% (4-19%) of YT2D patients had proteinuria (p<0.001 vs. GCK) and 21% 
(13-32%) had microalbuminuria (p<0.001). Neuropathy was rare in GCK patients (2% [0.3-
8%]) and controls (0% [0-4%]) but present in 29% (20-50%) of YT2D patients (p<0.001).  
GCK patients had a low prevalence of clinically significant macrovascular complications (4% 
[1-10%]) that was not significantly different from controls (11% [6-20%]; p=0.09), and lower 
in prevalence than YT2D patients (30% [21-41%], p<0.001). 
 
Conclusion 
Despite a median duration of 48.6 years of hyperglycemia, patients with a GCK mutation 
had low prevalence of microvascular and macrovascular complications. These findings 
may provide insights into the risks associated with isolated mild hyperglycemia.   
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Introduction 
In both type 1 (T1D)
1
 and type 2 diabetes (T2D)
2
 hyperglycemia over time is associated 
with microvascular complications.  Intensive treatment to lower blood glucose levels 
reduces the development of microvascular complications.
3,4
  In T1D, lowering the blood 
glucose has been shown to have long-term beneficial effects on reducing macrovascular 
disease
5
.  In T2D, the follow-up of the United Kingdom Prospective Diabetes Study 
(UKPDS) showed that lowering the level of hyperglycemia reduces the risk of 
macrovascular endpoints
6
.  Additionally, associations have been seen between measures 
of glycemia and coronary heart disease throughout the non-diabetic range
7
.  
 
Except for during pregnancy, a target hemoglobin A1c (HbA1c) <7% has been 
recommended for people with diabetes,
8,9
 yet longitudinal studies have few patients with 
sustained glycemia within this recommended target
1,2
.   It is therefore of clinical 
importance to know the complication prevalence and severity in individuals with a long 
and sustained duration of glycemia at a level above that of the non-diabetic population 
but that mimics the current target range of 7%.  Individuals with a heterozygous 
inactivating mutation in the GCK gene encoding the enzyme glucokinase have mild 
hyperglycemia that is present from birth.  Their HbA1c is typically between 5.6% and 
7.6%
10,11
 and their fasting plasma glucose between 5.5 and 8.7 mmol/l 
11,12
.  These 
patients rarely require pharmacological treatment
13
 and lipids and blood pressure are 
similar to the general population
14,15
.  The hyperglycemia in patients with a GCK 
mutation is therefore an isolated risk factor for complications 
14,15
.     
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We assessed the prevalence and severity of microvascular and macrovascular 
complications in patients with GCK mutations to give further information about the 
relationship between current glycemic targets and diabetes-related complications.  We 
also assessed these outcomes in non-diabetic, non-mutation carrying controls and patients 
with young-onset type 2 diabetes (YT2D).  
 
METHODS  
Study population 
The study was approved by the Devon and Torbay Research Ethics Committee, United 
Kingdom (UK) and the NHS Scotland Research Coordinating Centre, UK. Recruitment 
was undertaken between August 2008 and December 2010 and each patient provided 
written consent.  Individuals known to have a GCK mutation through genetic testing in 
Exeter (the UK testing center) were invited to participate.  The majority of patients with a 
GCK mutation were from the South West of England and Scotland, the two areas with 
the largest number of GCK cases in the UK.  All family members were invited to 
participate, both GCK mutation carriers and non-mutation carriers, if aged ≥18 years.  
Where genetic status was unknown in family members, diagnostic molecular genetic 
testing was performed to ascertain their mutation status, usually after the assessment of 
glycaemia and micro- and macrovascular complications.  To identify potential survival 
bias within families, we examined pedigrees of recruited GCK patients and assessed vital 
status of siblings and parents not recruited. We attempted to determine their mutation 
status, and when DNA of the deceased was not available, used the high penetrance of 
GCK-MODY mutations and autosomal dominant form of transmission to make obligate 
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assignments of mutation carriage to the diabetic parent of a known mutation carrier when 
the other parent was known not to have diabetes. Deaths were balanced between mutation 
and non-mutation carrier siblings and parents (see supplementary data).  
 
YT2D patients were diagnosed with Type 2 diabetes before the age of 45 years, did not 
use insulin therapy within one year of diagnosis, and were over 35 years at the time of the 
study.  These patients were recruited from an existing research cohort from South West 
England, prioritized by proximity to Exeter.  Patients unable to travel to Exeter were 
assessed at home or at a local hospital. 
 
Assessment of glycemia 
HbA1c was measured on all patients and analyzed in the biochemistry laboratory at 
the Royal Devon and Exeter NHS Foundation Trust (UK) on a Tosoh G8 anion 
exchange HPLC.   
 
Assessment of complications  
Detailed methods of assessments are described in the online supplementary data.   Data 
were collected by one of two researchers. The assessment of retinal photographs, 
biochemical measurements and ECG assessment were blinded to assignment. However, 
researchers were not always blinded to participant group during clinical assessments (see 
supplementary data). Inter-rater and intra-rater reliability analysis showed acceptable 
levels of measurement agreement (see supplementary data.  First void, mid-stream urine 
samples were analyzed to assess nephropathy.  Persistent microalbuminuria was 
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diagnosed when two albumin creatinine ratios (ACRs) were between 2.5 mg/mmol and 
30 mg/mmol (males) and 3.5 mg/mmol and 30 mg/mmol (females)
16
.  Proteinuria was 
diagnosed when two ACRs were >30mg/mmol (male or female) and reported as a 
protein/creatinine ratio.  Retinopathy was assessed using bilateral digital images. Images 
were graded by two readers, who were blinded to each other’s results, using the English 
Retinopathy Minimum Grading Classification
17
 (eTable 2).  Peripheral neuropathy was 
assessed using Vibration Perception Threshold.  Cutaneous perception was assessed using 
a 10g Semmes-Weinstein monofilament.  To assess peripheral vascular disease (PVD),  
intermittent claudication was defined by clinical diagnosis or by a positive San Diego 
Claudication Questionnaire 
18
 and the ankle-brachial pressure index was measured. To 
assess cardiovascular disease, patients completed the World Health Organization (Rose) 
chest pain questionnaire
19
.  A resting 12 lead electrocardiogram (ECG) was performed on 
those aged ≥40 years and assessed using Minnesota coding20.  Participant-reported 
episodes of angina, myocardial infarction (MI) and stroke were documented and 
confirmed by reviewing participants’ medical records. When adjudication of an endpoint 
was required this was provided by a senior clinician. 
 
Statistical Analysis 
The majority of data were not normally distributed so data are presented as median 
and inter-quartile range.  For the linear association between HbA1c and age, a 
bivariable linear regression model was used to determine the increase in HbA1c per 
year of age, with HbA1c as the dependent and age as the independent variable.  
Model assumptions of linearity between predictor and outcome, normality of 
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residuals, and homoscedasticity were checked and met. Comparisons of 
complications between groups were assessed using Mann Whitney U and Kruskal-
Wallis tests for continuous variables and Chi-squared and Fisher’s Exact tests for 
discrete variables.   
 
All significance tests were two sided and p<0.05 was considered statistically significant.  
Analysis was carried out using IBM SPSS Statistics v19. 
 
 
RESULTS  
We recruited 126 individuals aged >=18 years with an inactivating heterozygous GCK 
mutation (mutation details in eTable 1), 107 unaffected family members/spouses 
(controls), and 83 individuals with type 2 diabetes diagnosed ≤45 years (young-onset type 
2 diabetes (YT2D)) from across the UK.  All patients were white as reported by the 
patents’ referring clinicians.  Nine patients with a GCK mutation were excluded due to 
their potential for coincidental T1D or T2D. We identified these individuals using a 
robust outlier detection method as described by Horn to identify those above the normal 
range (HbA1c >7.6%).
21
 Two controls who met American Diabetes Association criteria 
for diabetes (HbA1c > 6.5%) were also removed from analysis.   
Figure 1 shows that patients of all ages with a GCK mutation have mild hyperglycemia as 
measured by HbA1c.  HbA1c was consistently higher in GCK patients (n=117) compared 
with controls (n=105) (median (IQR) 6.8%, 6.5-7.1 vs. 5.7%, 5.5-5.9 (p<0.001).  
Glycemic levels were higher in older GCK carriers and controls, with a slope of 0.17% 
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per year for GCK carriers (95% CI 0.12-0.22, p<0.001) and a slope of 0.12% per year 
(95% CI 0.08-0.16, p<0.001) in controls, p=0.1 for difference between slopes).  
To examine those most likely to have developed complications, assessments were 
performed in a subgroup of patients aged ≥35 years (99 GCK and 91 controls from 44 
families, and 83 YT2D).  We compared enrolled GCK patients with all UK GCK patients 
using data from the Molecular Genetics Diagnostic Laboratory, Exeter (UK).  The 99 
GCK patients were similar in age to the 360 UK patients known to have a GCK mutation 
(median (IQR) 48 (40, 62) vs. 49 (42, 61) years; p=0.90) but had a higher BMI (26.1 
(22.3, 29.6) vs. 24.5 (22.0, 28.0) kg/m
2
; p=0.05) and were different in gender distribution 
(20% vs. 32% male, p=0.02). The 83 YT2D participants were similar to the cohort of 397 
YT2D they were recruited from the Diabetes Alliance for Research in England, in age (54 
(49, 62) vs. 52 (46, 63) years; p=0.26), BMI (32.2 (28.3, 37.0) vs. 32.4 (28.0, 37.7) 
kg/m
2
; p=0.98), and gender (63% vs. 60% male, p=0.62). 
 
In the subgroup of patients aged ≥35 years, the level of hyperglycemia (HbA1c and FPG) 
was higher in GCK patients than in controls but milder than in patients with YT2D (Table 
1).  Duration of hyperglycemia was longer in patients with a GCK mutation (48 years 
(median), duration equal to current age) compared with YT2D patients (known to have 
diabetes for 17 years (median), p<0.001).  22% of patients with a GCK mutation were 
taking glucose lowering agents (0% insulin) compared with 90% of YT2D patients (60% 
insulin), p<0.001 (Table 1).    
 
Microvascular Complications  
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Overall, the prevalence of clinically significant microvascular complications 
(>background retinopathy or persistent microalbuminuria or proteinuria) was low in 
patients with a GCK mutation (1% [95% CI 0-6%]) and not significantly different from 
controls (2% [0.2-8%], p=0.52).  In contrast, 36% (95% CI: 25, 47%) of the YT2D 
patients had evidence of clinically significant microvascular disease (p<0.001 vs GCK 
mutation patients) (Table 3).  
 
Persistent microalbuminuria was rare in patients with a GCK mutation (1/97 (1% (95% 
CI: 0.2, 6%)) and in controls (2/89 (2% (95% CI: 0.2, 8%)) (Table 3).  This rate was 
lower than that seen in YT2D where 17/80 (21% (95% CI: 13, 32%)) were identified 
(p<0.001 vs. GCK mutation patients).   Zero patients had persistent proteinuria in the 
GCK and control groups whereas 8/80 (10% (95% CI: 4, 19%)) of YT2D patients had 
this condition (p<0.001 vs. GCK mutation patients). 
 
A higher prevalence of any level of retinopathy was seen GCK mutation carriers 
compared with controls (27/90, 30% (95% CI: 21, 41%) vs. 12/87, 14% (7, 23%), 
p=0.007).  However, this was exclusively due to background retinopathy, and 22/27 
(81%) of those with background retinopathy had minimal disease with fewer than five 
microaneurysms.  A larger percentage of those with YT2D had any retinopathy 
(52/83(63% (95% CI: 51, 73%), p<0.001 vs. GCK mutation patients).  Additionally, the 
degree of retinopathy in the YT2D group was more severe, with maculopathy in 17/83 
(20% (95% CI: 12, 31%)) patients compared to 0/90 GCK mutation patients (p<0.001) 
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and laser therapy in 23/83 (28% (95% CI: 18, 39%)) patients compared to 0/90 GCK 
mutation patients (p<0.001).     
 
Peripheral neuropathy was rare in patients with GCK mutations (2/93 (2% (95% CI: 0.3, 
8%))) and zero cases were found in controls (0% (95% CI: 0, 4%)).  In contrast, 24/83 
(29% (95% CI: 20, 50%)) of the YT2D group had peripheral neuropathy (p<0.001 vs. 
GCK mutation patients). 
 
Macrovascular Complications  
The prevalence of known clinically diagnosed macrovascular complications was low in 
patients with a GCK mutation and controls (4/99, 4% (95% CI: 1, 10%) and 10/91, 11% 
(95% CI: 5, 19%) respectively).  This contrasts with the YT2D patients where 30% (95% 
CI: 21, 41) had clinically diagnosed macrovascular disease (p<0.001, Table 2).  
 
There were zero cases of intermittent claudication in patients with a GCK mutation or 
controls and 5/83 (6% (95% CI: 0, 13%)) in the YT2D group (Table 3).  The prevalence 
of PVD (ABPI <0.5 or ABPI ≥ 1.40 or amputation or intermittent claudication) was low 
in patients with a GCK mutation and controls (1% and 3% respectively).  The prevalence 
was significantly higher in the YT2D group (13/83 (16% (95% CI:8, 25%)), p<0.001 vs 
GCK mutation patients).   
 
The presence of ischemic heart disease (IHD) was low in patients with a GCK mutation 
(2/99, 2% (95% CI: 0.2-7%)) and controls (5/91 ,5% (95% CI: 2-13%)).  The prevalence 
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of IHD was higher in YT2D patients (13/83 (16% (95% CI: 10-29%)), p=0.001 vs. GCK 
mutation patients). Minnesota coding identified probable coronary disease in 9/69 (13%) 
of patients with a GCK mutation and 20/81 (25%) of controls, and in 19/75 (25%) of 
YT2D patients.  Zero patients in either the GCK or control groups had suffered from a 
stroke compared with 4/83 patients (5%) in the YT2D group. 
 
DISCUSSION 
Patients with a GCK mutation have a low prevalence of clinically significant 
microvascular and macrovascular complications despite their hyperglycemia since birth 
10,11
.  In these patients, an average of nearly fifty years of isolated hyperglycemia within 
current target ranges for diabetes control had a negligible association with complication 
development.  This work is, to our knowledge, the first systematic assessment of 
complication development in patients with a GCK mutation.   
 
Previous studies have suggested that complications are rare in patients with GCK 
mutations, 
10,14,15
 but, unlike our study, these studies mainly used data from clinical 
notes
10,15
, reviewed a small number of patients
10,14
, did not include a control group
10,15,22
 
or had a mean age of study of <37 years
10,14,15
.  We have used clinically recognized and 
standardized techniques for each participant, with high levels of intra and inter-observer 
reproducibility and reliability.  The prevalence and severity of complications in patients 
with GCK mutations was similar to that of controls.  The presence of complications in 
our control group was not surprising, as hyperglycemia related complications have 
previously been reported in the general population
23-27
. In contrast to other studies, we 
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have addressed the potential issues of selection bias and survival bias. The GCK and 
YT2D patients were generally representative of the large cohorts from which they were 
selected.  There is no evidence to suggest that GCK patients were excluded from the 
study because of premature death.   
 
Retinopathy (evidence of at least one microaneurysm) in people without diabetes occurs in 
5–9% of the non-diabetic general population with an age range of 43-84 years25,28.  The 
prevalence of background retinopathy in our control group was similar.  We did identify a 
higher prevalence rate for background retinopathy in our patients with a GCK mutation, but 
the vast majority of these patients had mild background retinopathy with <5 microaneurysms.  
None of our patients with a GCK mutation had sight-threatening retinal disease.  Previous 
studies in GCK mutation carriers found prevalence rates of proliferative retinopathy of 0-
4%
14,15,22
.  These studies used direct fundoscopy, whereas we used digital retinal imaging 
with primary, secondary and where required, arbitration grading and did not exclude 
concomitant Type 1 or Type 2 diabetes.   
 
All other microvascular complications had comparably low prevalence rates in patients 
with a GCK mutation and in controls.  Microalbuminuria has been reported in 6.6-9.4% 
of the non-diabetic population
23,24
 and in 0-6% of patients with a GCK mutation
10,14,15,29
.  
Rather than relying on urinalysis sticks as in previous GCK studies
15,22
 we excluded UTI 
and biochemically confirmed the diagnosis of microalbuminuria with 3 consecutive early 
morning urine samples.  Our prevalence rates were similar to those previously reported in 
patients with a GCK mutation, but were lower than previously reported in the general 
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population.  We did not identify any GCK patients with proteinuria. The prevalence of 
neuropathy was also low in GCK patients and controls in our study.   Previous studies 
have reported a prevalence of 4-5% in GCK patients
10,14,15,29
. 
 
An increase in HbA1c of 1% results in a 10-20% increase in CVD risk and predicts 
cardiovascular risk both in people with diabetes and in the general population 
30
.  Our 
data suggest that macrovascular complications are not increased in individuals with GCK 
mutations and are in keeping with earlier studies reporting a prevalence of cardiovascular 
disease between 0.7-12%
10,14,15
.  Our finding of a low prevalence of CVD in the GCK 
mutation carrier group, even with their slightly elevated HbA1c, provides evidence that 
isolated hyperglycemia is rarely associated with macrovascular complications. Although 
treatment is not advocated in patients with a GCK mutation outside pregnancy, 22% of 
our GCK cohort were treated with glucose lowering agents which is consistent with 
previous studies
13,22
.  Recent work has shown that pharmacological treatment does not 
alter HbA1c in patients with a GCK mutation, so this is unlikely to confound our 
findings
13
.  
 
We have shown that patients with GCK mutations, who have mild hyperglycemia from 
birth, have significantly lower diabetes related complication prevalence and severity 
when compared to individuals with a shorter duration of more severe hyperglycemia 
(YT2D).  Retinopathy, nephropathy, peripheral neuropathy and angina were all 
significantly more common in the YT2D group.  However, several considerations warrant 
mentioning prior to extrapolating findings in patients with glucokinase mutations to other 
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subtypes of diabetes.  Patients with GCK mutations have been shown to have a similar 
degree of insulin resistance and obesity as the general population
14,15
 whereas the YT2D 
cohort has been exposed to many metabolic risk factors for complication development.  
Obesity, hypertension and dyslipidaemia found in T2D may alter the impact of glycaemia 
on the risk of complications. T1D and T2D patients have a more variable blood glucose 
profile compared with patients with a GCK mutation; this variability may impact on the 
complication prevalence and severity rates.  Patients with GCK mutations are born with 
hyperglycemia so there may be early compensation for this, resulting in protection from 
vascular complications.  It also means that GCK mutation patients are younger than 
patients diagnosed with diabetes later in life with the same duration of hyperglycemia.  
Age as well as duration is likely to be important in complication development.  Despite 
these caveats, our ability to study individuals with isolated hyperglycemia has provided a 
useful natural experiment for understanding the development of complications.  
 
Our study is limited by the relatively small number of patients known to have GCK 
mutations, which necessitates a cross sectional study rather than a longitudinal study and 
limits power.  Although the prevalence of complications was low both in patients with a 
GCK mutation and controls, we are unable to prove equivalence with our sample size.  
We would need a control group over 10 times larger to detect statistical significance 
between patients with GCK mutations and controls at the prevalences we observed.  
However, with the exception of mild background retinopathy, the prevalence of all 
complications was very low in GCK mutation patients, with similar confidence intervals 
to controls, and significantly lower than those seen in the YT2D group.  Even if proved to 
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be statistically different, it is unlikely that differences between the low prevalence rates 
seen would be of clinical significance.  Our definition of the YT2D cohort’s duration of 
hyperglycemia is not precise: individuals may be unaware they have T2D and 
complications can occur in up to 50% of people before a medical diagnosis for symptoms 
is sought 
31
.  Even with this likely underestimation of duration of hyperglycemia in the 
YT2D cohort, their duration will not be as long as the patients with a GCK mutation, 
whose hyperglycemia is present from birth.  Because the researchers who conducted 
clinical assessments on macrovascular disease were aware of the clinical category of 
many of the patients, not all clinical assessments were collected in a blinded fashion. 
Finally, there were more females recruited in our GCK mutation group.  This is unlikely 
to impact microvascular disease rates but could affect macrovascular disease rates.  With 
so few cases in the GCK group, it is not possible to adjust for this difference statistically.  
However, the prevalence of coronary heart disease in the GCK mutation group for both 
men and women is similar to that reported in England for a similar age range (45-54 
years)
32
: 5% v 3.6% in men and 1.2% vs. 1.3% in women.  Although these results are 
similar to those of the general population, our confidence intervals were wide and larger 
numbers would be required to investigate this further. 
 
Conclusions   
Patients with GCK mutations over a median of 48.6 years had a low prevalence of 
vascular complications.  These findings provide insights into the risks associated with 
isolated mild hyperglycemia. 
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Figure Legends 
 
Figure 1. Scatterplot of HbA1c by age in GCK patients (n=117, black circles) compared 
with controls (unaffected family members, n=105, white circles).  Regression lines show 
increasing HbA1c with age (dashed = controls, solid = GCK), p=0.1 for the difference 
between the lines.     
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Table 1: Characteristics of the three groups studied.  Data presented as median (IQR) or % 
 
Characteristics GCK (n=99) Controls (n=91*) YT2D (n=83) GCK v Controls  
P Value 
 
GCK v YT2D 
P Value 
 
Gender:  n (%) male 20/99 (20%) 41/91 (45%) 52/83 (63%) <0.001 <0.001 
Current Age (years) 48.6 (40.1-62.7) 52.2 (42.3-64.8) 54.7 (49.2-62.0) 0.49 0.06 
Body Mass Index (kg/m
2
) 26.1 (22.3-29.3) 28.0 (25.3-31.2) 32.2  (28.3-37.1) 0.004 <0.001 
Age hyperglycemia/diabetes diagnosis 
(years) 
33 (24-44) N/A 40 (35-42) N/A 0.001 
Duration hyperglycemia (years) 48 (40-62) N/A 17 (9-23) N/A  <0.001 
Fasting Plasma Glucose (mmol/l) 7.0 (6.6-7.5) 5.2 (4.8-5.6) 8.0 (6.2-10.4) <0.001 <0.001 
HbA1c (%)  6.9 (6.5-7.1) 5.8 (5.5-5.9) 7.8 (7.2-8.7) <0.001 <0.001 
On glucose lowering agents: n (%) 22/99 (22%) N/A 75/83 (90%) N/A <0.001 
Systolic Blood Pressure (mm/Hg) 125 (116-141) 128 (119-140) 135 (123-149) 0.65 0.004 
Diastolic Blood Pressure (mm/Hg)   78 (72-84) 79 (74-86) 79 (71-89) 0.31 0.38 
% on antihypertensive treatment 25/99 (25%) 19/91 (21%) 56/83 (68%) 0.48 <0.001 
Total cholesterol (mmol/L) 4.8 (4.2-5.4) 5.1 (4.5-6.0) 4.2 (3.7-4.8) 0.03 <0.001 
Triglycerides (mmol/L) 0.97 (0.78-1.23) 1.15 (0.81-1.56) 1.49 (1.14-2.59) 0.03 <0.001 
High Density Lipoproteins (mmol/L) 1.57 (1.27-2.00) 1.47 (1.26-1.76) 1.09 (0.95-1.39) 0.07 <0.001 
Low Density Lipoproteins (mmol/L) 2.66 (2.14-3.27) 3.04 (2.44-3.92) 2.07 (1.66-2.50)  0.01 <0.001 
Cholesterol/HDL ratio 2.9 (2.4-3.7) 3.5 (2.8-4.2) 3.6 (2.9-4.5) 0.002 <0.001 
On lipid lowering treatment: n (%) 25/99 (26%) 11/91 (12%) 68/83 (82%) 0.02 <0.001 
estimated Glomerular Filtration Rate
a 
(ml/min/1.73m
2
) 
82 (68-92) 84 (73-93) 81 (62-100) 0.20 0.80 
Smoking status: n (%) 
Never  
Ever 
 
59/99 (60%) 
40/99 (40%) 
 
45/91 (49%) 
46/91 (51%) 
 
28/83 (34%) 
55/83 (66%) 
 
0.16 
 
0.001 
 
 
a
Measured using the 4-variable modification of diet in renal disease equation (MDRD) estimation of glomerular filtration rate (eGFR) 
16
. 
*First degree relatives n=32, second degree relatives n=9, spouses n=38, distant relative n=3, non-blood relative n=9  
Abbreviations: N/A: not applicable 
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Table 2: Prevalence of clinically significant microvascular and clinically significant macrovascular disease alone in patients with GCK 
mutations (GCK), controls and young type2 diabetes (YT2D).  Clinically significant microvascular disease is greater than background retinopathy 
OR persistent microalbuminuria OR persistent proteinuria.  Clinically significant macrovascular disease is intermittent claudication OR amputation  
OR  angina  OR myocardial infarction OR stroke   
 
 
 
 
 
  
 GCK Controls YT2D GCK v 
controls  
P Value 
GCK v 
YT2D  
 P Value 
Clinically significant Microvascular disease alone 1/99 (1% (0-5))  0/91 (0% (0-4)) 19/83 (23% (14-33)) 0.5 <0.001 
Clinically significant Macrovascular disease alone 4/99 (4% (1-10)) 8/91 (9% (4-17)) 14/83 (17% (10-27)) 0.19 0.004 
Clinically significant Microvascular and 
Macrovascular disease 
 0/99 (0% (0-4)) 2/91 (2% (0.3-8%)) 11/83 (13% (7-22)) 0.23 <0.001 
Total affected with clinically significant Microvascular 
and Macrovascular disease 
5/99 (5% (2-11)) 10/91 (11% (5-19)) 44/83 (53% (42-64)) 0.14 <0.001 
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Table 3: Prevalence and severity of complications in the three groups.  Data presented as n (% (95%CI)) 
 
  GCK  
(n=99) 
Controls 
 (n=91) 
YT2D  
(n=83) 
GCK v 
Controls 
P value 
GCK v  
YT2D 
P value 
Microvascular Complications 
Renal complications Persistent microalbuminuria 1/97 (1% (0.2-6)) 2/89 (2% (0.2-8)) 17/80 (21% (13-32)) 0.60 <0.001 
 Proteinuria 0/97 (0% (0-4)) 0/91 (0% (0-4)) 8/80 (10% (4-19)) >0.99 <0.001 
Retinal complications Any degree of retinopathy 27/90 (30% (21-41)) 12/87 (14% (7-23)) 52/83 (63% (51-73)) 0.007 <0.001 
 Background retinopathy alone 
<5 microaneurysms 
>5 microaneurysms 
27/90 (30% (21-41)) 
22/27 (81% (62-94)) 
5/27 (19% (6-38)) 
12/87 (14% (7-23)) 
12/12 (100% (74-100)) 
0/12 (0% (0-26)) 
28/83 (34% (24-45)) 
13/28 (46% (28-66))  
15/28 (54% (34-72)) 
 
0.02 
 
0.6 
 Pre-proliferative retinopathy 0/90 (0% (0-4)) 0/87 (0% (0-4)) 7/83 (8% (3-17)) >0.99 0.005 
 Proliferative retinopathy 0/90 (0% (0-4)) 0/87 (0% (0-4)) 8/83 (10% (4-18)) >0.99 0.002 
 Advanced eye disease 0/90 (0% (0-4)) 0/87 (0% (0-4)) 3/83 (4% (1-10)) >0.99 0.005 
 Maculopathy 0/90 (0% (0-4)) 0/87 (0% (0-4)) 17/83 (20% (12-31)) >0.99 <0.001 
 Laser therapy for retinopathy 0/90 (0% (0-4)) 0/87 (0% (0-4)) 23/83 (28% (18-39)) >0.99 <0.001 
Peripheral 
neuropathy 
VPT >25v mean or  monofilament ≤3sites 2/93 (2% (0.3-8)) 0/89 (0% (0-4)) 24/83 (29% (20-50)) 0.16 <0.001 
Clinically significant 
microvascular disease 
>background retinopathy OR persistent 
microalbuminuria OR proteinuria 
1/99 (1% (0-5)) 2/91 (2% (0.3-8)) 30/83 (36% (25-47)) 0.52 <0.0001 
 
Macrovascular Complications 
Vascular 
complications 
Intermittent claudication 
Clinically diagnosed OR positive San Diego questionnaire 
 
0/97 (0% (0-4)) 
 
0/91 (0% (0-4)) 
 
5/83 (6% (0-13)) 
 
>0.99 
 
0.14 
 Significantly reduced ABPABPI <5.0  0/97 (0% 0-3)) 0/91 (0% (0-3)) 0/83 (0% 0-4)) >0.99 >0.99 
 Significantly increased ABPI 
ABPI ≥1.40  
1/97 (1% (0.2-6)) 3/91 (3% (0.7-9)) 9/83 (11% (5-20)) 0.30 0.006 
 Amputation 0/97 (0% (0-4)) 0/91 (0% (0-4)) 4/83 (5% (1-12)) 0.10 0.04 
 Peripheral Vascular Disease 
Clinically diagnosed OR ABPI <0.5 OR ABPI ≥1.40 OR 
amputation OR positive San Diego questionnaire 
 
1/93 (1% (0-5)) 
 
3/89 (3% (0-9)) 
 
13/83 (16% (8-25)) 
 
0.30 
 
0.0004 
 Angina 
Clinically diagnosed OR positive Rose angina 
questionnaire 
 
4/93 (4% (1-10)) 
 
10/89 (11% (5-19)) 
 
18/83 (22% (13-32)) 
 
0.07 
 
<0.001 
 Myocardial Infarction 2/89 (2% (0.2-7)) 2/97 (2% (0.2-8)) 5/83 (6% (2-14)) 0.99 0.16 
 Ischemic Heart disease 
(Myocardial Infarction OR Angina) 
2/99 (2% (0.2-7)) 5/91 (5% (2-13)) 13/83 (16% (10-29))  0.32 0.001 
 Minnesota coding: Coronary disease probable  9/69 (13% (6-23)) 20/81 (25% (16-36)) 19/75 (25% (16-37)) 0.07 0.06 
Cerebral vascular 
events 
Stroke 0/99 (0% (0-4)) 0/91 (0% (0-4)) 4/83 (5% (1-12)) >0.99 0.04 
Clinically diagnosed 
macrovascular disease 
Intermittent claudication OR  Amputation OR  Angina  
OR Myocardial Infarction OR Stroke   
 
4/99 (4% (1-10)) 
 
10/91 (11% (5-19)) 
 
25/83 (30% (21-41)) 
 
0.09 
 
<0.001 
 
